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Systemic lupus erythematosus (SLE) is an autoimmune disease more prominent in women and characterized by multiple organ
damage. Imbalance in cytokine production and cytokine levels correlates with SLE progression, making the understanding of SLE
cytokine networks very important for SLE treatment strategy and drug development. In this article, we review cytokine networks
that may be involved in the pathogenesis of SLE by brieﬂy describing abnormal cytokine production and serum cytokine levels in
SLEpatients.Wealsofocusonthepathologicalrolesofcytokinesandtheirinteractionsinimmunoregulatorynetworksandsuggest
how their disturbances may implicate in pathological conditions in SLE. Finally, we further discuss the inﬂuence of estrogen on
these cytokine networks.
1.Introduction
Systemic lupus erythematosus (SLE) is a prototypical sys-
temic autoimmune disease characterized by multiple organ
damage, high titers of autoantibodies, and various clinical
manifestations [1]. There is a 10–15 times higher frequency
of SLE in women during childbearing years, probably due to
an estrogen hormonal eﬀect [2]. Aberrant biological activi-
ties by numerous cytokines have been described in patients
with SLE. Despite concerted eﬀort to unravel the patholog-
ical roles of individual cytokines in SLE, the considerable
redundancy and pleiotropism of cytokine characteristics has
kept their functions poorly understood. However, signiﬁcant
progress in microarray techniques as well as advances
in biological databases has given us new perspective on
autoimmune diseases in general including the complicated
pathogenesis and heterogeneous manifestations like those
seen in SLE. These breakthroughs show promise for the
next great leap in understanding the immunoregulatory
networks of autoimmune diseases that are inﬂuenced by
multiple factors, with speciﬁc emphasis on cytokines and
their interactions, in other words, cytokine networks.
In this article, we present current knowledge regarding
abnormal cytokine networks that may be involved in the
pathogenesis of SLE. First, we provide a brief description
of the abnormal cytokine production and serum cytokine
levels in patients with SLE. Subsequently, we focus on
the pathological roles of cytokines, in particularly tumor
necrosis factor (TNF) and interferon (IFN), as well as
cytokine interactions in immunoregulatory networks and
suggest how their disturbances may trigger SLE pathologies.
Finally, we further discuss the inﬂuence of estrogen on
cytokine networks.
2. Cytokine Productions and Cytokine Levels in
Patients withSLE
It is thought that the balance between proinﬂammatory
and anti-inﬂammatory cytokines inﬂuences the clinical
manifestations in many inﬂammatory diseases such as SLE
and rheumatoid arthritis (RA). These cytokines are mainly
produced by helper T (Th) cells, which can be divided
into several subsets according to their distinct proﬁles [3].
We review several relevant cytokines by discussing their
production, serum levels, and roles in SLE below.
Several groups have studied individual cytokines that
are produced diﬀerently between patients with SLE from2 Journal of Biomedicine and Biotechnology
either healthy individuals or those suﬀering from rheumatic
diseases, like RA [4, 5]. Patients with active SLE have
been reported to have signiﬁcantly higher levels of serum
proinﬂammatory cytokines, tumor necrosis factor (TNF),
and interleukin (IL)-6 [6–8]. However, one study found that
serum TNF concentrations did not diﬀer from controls,
instead observing that increased levels of soluble TNF
receptor (TNF-sR) correlated positively with the degree of
disease activity [9]. TNF-sR is an antagonist to TNF and
therefore decreases TNF activity. Elevated serum IL-6 levels
m a yb ed u et oe n v i r o n m e n t a lf a c t o r ss i n c ee x p o s u r et oU V
light has been shown stimulate the monocyte/macrophage
fraction of peripheral blood mononuclear cells (PBMCs)
taken from patients with SLE to produce IL-6 [10]. Elevation
ofserumIL-10 concentrationandits correlation withdisease
activityhasalsobeendescribedinSLEpatients[11–13].Both
constitutive and stimulated levels of the anti-inﬂammatory
cytokine transforming growth factor (TGF)β have been
reported to be lower in patients with SLE, probably because
high levels of IL-10 should suppress TGFβ production by
natural killer (NK) cells [14]. The high immunoglobulin
(Ig)G production seen in SLE patients may be a consequence
of low TGFβ levels, as TGFβ suppresses B lymphocyte
secretion of IgG via CD8+ cells in presence of IL-2 [15]. A
recent pilot clinical study showed that Tocilizumab, an IL-
6 receptor inhibitor, decreased IgG levels in SLE patients,
suggesting that high levels of IL-6 may also contribute to
high IgG [16]. TGFβ converts naive T cells into regulatory T
cells, which can then prevent autoimmunity. However, in the
presence of IL-6, TGFβ also promotes the diﬀerentiation of
naive T lymphocytes into proinﬂammatory IL-17-producing
Th17 cells, resulting in autoimmunity and inﬂammation [3].
Despite many reports showing the pathological role of IL-
17 in RA, few have made this connection in SLE [17–19],
although increased plasma IL-17 levels have been reported
[20].
Furthermore, type I IFN and type II IFN have both been
implicated in the pathogenesis of SLE. High IFN-α and IFN-
γ serum levels have been reported in SLE [4, 21–24]. Patients
with active SLE often present ﬂu-like symptoms such as fever
and fatigue, both of which reﬂect high serum IFN-α levels
and are relevant to disease activity and severity [25–27].
The major producer of IFN-α is the cell subset plasmacytoid
dendritic cells (pDCs) [28]. Two groups have identiﬁed
large numbers of IFN-producing pDCs in cutaneous LE skin
lesions[29,30].Decreasednumbersinperipheralbloodhave
also been reported, suggesting the potential ability of pDCs
to migrate toward peripheral tissues [31–34]. Although our
previous report did not identify any overexpression of the
IFN-α gene in peripheral blood cells from SLE patients [35],
we have found the overexpression of several IFN-inducible
(IFI) genes, which agrees with other reports showing that
peripheral blood from SLE patients has remarkably homoge-
neous gene expression patterns including an overexpression
of IFI genes, implying IFN involvement in SLE [36–40].
Finally, in the cerebrospinal ﬂuid (CSF) of SLE patients
with central nervous system (CNS) pathologies, elevated
concentrations of TNF, IL-1, IL-6, and IL-10 have been
reported [41, 42]. IL-6 and IFN-γ have also been found in
kidney biopsy specimens from patients with lupus nephritis
[32, 43].
3. InteractionsAmongIFN-α,IFN-β,andTNFin
the Immunoregulatory Networks of SLE
Aberrant regulations or interactions among immune
response molecules have been reported in our previous
study [35]. TNF and IFN-γ have been observed to play
central roles in the immunoregulatory networks of SLE,
which mainly include IFI molecules. Studies on the eﬀect
of interactions between IFN-α and one of TNF or IFN-γ
on the expression of IFI molecules found that TNF has a
repressive eﬀect while IFN-γ mainly has a synergistic eﬀect
on the regulation of IFI gene expressions induced by IFN-α
in vitro. Although the exact function of IFI molecules in SLE
pathogenesis is still obscure, we suspect that the increased
serum TNF level in SLE compensates for the immune system
balancealteredbyIFN-α in SLE. More than 10 yearsago, SLE
patients with “low” PBMC TNF production were found to
be more likely to develop nephritis [44]. In addition, patients
with RA or Crohn’s disease can develop autoantibodies to
nuclear antigens when under TNF blocking therapies [45].
It has also been reported that patients on anti-TNF therapy
display increased transcription of IFN-α-regulated genes
and that TNF inhibits virus-induced IFN-α release by both
healthy and SLE PBMCs [46]. All these evidences further
implicate that a strong TNF response is protective against
lupus nephritis and that therapeutic TNF blockaders could
exacerbate SLE or provoke lupus-like manifestations. With
regards to IFN-γ, SLE patients have been found to have
genetic deﬁciencies and abnormal overexpression in the
aﬀected organs [32, 43, 47–51]. IFN-γ receptor knockout
lupus prone mouse strain has suggested that IFN-γ is
essential for the development of nephritis in mice and that
increasing IFN-γ during disease activation may cause an
increase in IgG [52]. A recent study has also described
activation of the IFN-γ signaling pathway in the PBMCs of
patients with SLE [53], supporting the notion that IFN-γ
has a pathological role in SLE development. Although the
mechanisms of increased IFN-γ serum levels in SLE are
still unknown, together with our results, the synergistic
eﬀect of IFN-γ with IFN-α seems to accelerate SLE disease
development.
4. Inﬂuence of Estrogen in Cytokine Networks
Several studies have suggested that gender diﬀerences in
lupus susceptibility are mediated by sex hormones, consis-
tent with the fact that 90% of SLE suﬀerers are female [54–
56].Forexample,thereisanincreasedriskofdevelopingSLE
in postmenopausal women who received estrogen hormone
replacement therapy [57]. The role of estrogen in cytokine
networks has been well investigated in pregnant women.
Cytokines areintimately involved withsexhormones, asthey
regulate the level of sex hormones both systemically and
locally, especially in the reproductive organs. Complicated
interactions in cytokine-steroid networks aﬀect cell activitiesJournal of Biomedicine and Biotechnology 3
such as proliferation and apoptosis [58]. It has been reported
that a shift in the Th1 to Th2 ratio impacts immunological
changes in maternal circulation during gestation due to the
progressive increase of estrogens that reach peak level during
the third trimester of pregnancy. It seems that estrogens
inhibit cell-mediated immune response (Th1 cytokines),
whereas they induce antibody production (Th2 cytokines)
[59]. However, it has been shown that serum levels of
estrogens are lower in SLE patients in the third trimester of
pregnancycomparedtohealthycontrolsandthatthismaybe
due to compromised placental activities [60]. On the other
hand, IL-6 progressively increases in maternal circulation
in healthy individuals during pregnancy, but low levels of
IL-6 have also been reported during the third trimester
of pregnancy in SLE patients [61]. Therefore, low levels
of estrogens and IL-6 are thought to be responsible for
lower activation of the humoral immune response, which
then leads to the lower disease activity observed over the
same period in SLE patients [59]. Our previous report
also shows that beta-estradiol plays a signiﬁcant role in the
immunoregulatory networks of SLE, although the in vitro
results did not show any strong evidence for a functional
interaction between estradiol and IFN-α on the expression
of IFI genes [35]. Taken together, beta-estradiol too plays a
signiﬁcant role in the pathophysiology of SLE. Ultimately,
we can see that complex interactions between hormones and
cytokines have a strong eﬀect on autoimmune diseases, but
the details are still poorly grasped.
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